Canada · Delayed Price · Currency is CAD Bright Minds Biosciences Statistics
Total Valuation
CSE:DRUG has a market cap or net worth of CAD 929.98 million. The enterprise value is 622.22 million.
| Market Cap | 929.98M |
| Enterprise Value | 622.22M |
Important Dates
The next estimated earnings date is Wednesday, December 23, 2026.
| Earnings Date | Dec 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:DRUG has 9.86 million shares outstanding. The number of shares has increased by 38.94% in one year.
| Current Share Class | 9.86M |
| Shares Outstanding | 9.86M |
| Shares Change (YoY) | +38.94% |
| Shares Change (QoQ) | +2.51% |
| Owned by Insiders (%) | 16.73% |
| Owned by Institutions (%) | 74.50% |
| Float | 6.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.02 |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 121.97, with a Debt / Equity ratio of 0.00.
| Current Ratio | 121.97 |
| Quick Ratio | 121.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -753.50 |
Financial Efficiency
Return on equity (ROE) is -13.63% and return on invested capital (ROIC) is -13.61%.
| Return on Equity (ROE) | -13.63% |
| Return on Assets (ROA) | -13.50% |
| Return on Invested Capital (ROIC) | -13.61% |
| Return on Capital Employed (ROCE) | -12.73% |
| Weighted Average Cost of Capital (WACC) | 4.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -942,646 |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +70.57% in the last 52 weeks. The beta is 0.09, so CSE:DRUG's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +70.57% |
| 50-Day Moving Average | 103.56 |
| 200-Day Moving Average | 106.55 |
| Relative Strength Index (RSI) | 33.31 |
| Average Volume (20 Days) | 592 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.18M |
| Pretax Income | -24.51M |
| Net Income | -24.51M |
| EBITDA | n/a |
| EBIT | -39.18M |
| Earnings Per Share (EPS) | -2.86 |
Balance Sheet
The company has 307.83 million in cash and 65,589 in debt, with a net cash position of 307.76 million or 31.20 per share.
| Cash & Cash Equivalents | 307.83M |
| Total Debt | 65,589 |
| Net Cash | 307.76M |
| Net Cash Per Share | 31.20 |
| Equity (Book Value) | 307.79M |
| Book Value Per Share | 31.20 |
| Working Capital | 307.74M |
Cash Flow
| Operating Cash Flow | -24.67M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 76,057 |
| Net Borrowing | -104,771 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:DRUG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.94% |
| Shareholder Yield | -38.94% |
| Earnings Yield | -2.64% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for CSE:DRUG is 129.33, which is 40.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 129.33 |
| Price Target Difference | 40.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on July 14, 2023. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jul 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |